Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Farmers Insurance
Express Scripts
Covington
Queensland Health
Dow
UBS
Moodys
Deloitte
US Department of Justice

Generated: April 21, 2018

DrugPatentWatch Database Preview

Estradiol acetate - Generic Drug Details

« Back to Dashboard

What are the generic sources for estradiol acetate and what is the scope of estradiol acetate freedom to operate?

Estradiol acetate
is the generic ingredient in two branded drugs marketed by Apil and is included in two NDAs. There are three patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Estradiol acetate has eleven patent family members in ten countries.

There are seventy-five drug master file entries for estradiol acetate. Two suppliers are listed for this compound.
Pharmacology for estradiol acetate
Ingredient-typeEstradiol Congeners
Drug ClassEstrogen
Mechanism of ActionEstrogen Receptor Agonists
Synonyms for estradiol acetate
(14S,15S)-14-HYDROXY-15-METHYLTETRACYCLO[8.7.0.0(2),?.0(1)(1),(1)?]HEPTADECA-2(7),3,5-TRIEN-5-YL ACETATE
[(13S,17S)-17-hydroxy-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthren-3-yl] acetate
17beta-Estradiol 3-acetate
17beta-Hydroxy-3-acetoxyestra-1,3,5(10)-triene
17beta-Hydroxyestra-1,3,5(10)-trien-3-yl acetate
25975-62-6
3-(Acetyloxy)estra-1,3,5(10)-trien-17.beta.-ol
3-Acetoxy-oestra-1,3,5(10)-trien-17beta-ol
3-Acetoxyestra-1,3,5(10)-trien-17beta-ol
3-O-Acetylestradiol
4245-41-4
5R97F5H93P
AC1L4HAE
beta-Estradiol 3-acetate
CAS-4245-41-4
CHEBI:135981
CHEMBL1200430
D04061
D0T7ZQ
DSSTox_CID_25867
DSSTox_GSID_45867
DSSTox_RID_81186
DTXSID7045867
E 3A
E3A
Estra-1,3,5(10)-triene-3,17-diol, (17 beta)-, 3-acetate
Estra-1,3,5(10)-triene-3,17-diol, (17 beta)-, 3-acetate
Estra-1,3,5(10)-triene-3,17-diol, (17beta)-, 3-acetate
Estra-1,3,5(10)-triene-3,17beta-diyl 3-acetate
Estradiol 3-acetate
Estradiol acetate (USAN)
Estradiol acetate [USAN]
Estradiol-3-acetate
Estradiol, 3-acetate
Femring
FHXBMXJMKMWVRG-SLHNCBLASA-N
LS-182995
Menoring
NCGC00249885-01
PL005857
SCHEMBL148561
Tox21_111359
Tox21_113661
UNII-5R97F5H93P

US Patents and Regulatory Information for estradiol acetate

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Apil FEMTRACE estradiol acetate TABLET;ORAL 021633-003 Aug 20, 2004 DISCN Yes No ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Apil FEMRING estradiol acetate INSERT, EXTENDED RELEASE;VAGINAL 021367-002 Mar 20, 2003 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Apil FEMTRACE estradiol acetate TABLET;ORAL 021633-001 Aug 20, 2004 DISCN Yes No ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Apil FEMTRACE estradiol acetate TABLET;ORAL 021633-003 Aug 20, 2004 DISCN Yes No ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Expired US Patents for estradiol acetate

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Apil FEMRING estradiol acetate INSERT, EXTENDED RELEASE;VAGINAL 021367-001 Mar 20, 2003 ➤ Try a Free Trial ➤ Try a Free Trial
Apil FEMRING estradiol acetate INSERT, EXTENDED RELEASE;VAGINAL 021367-002 Mar 20, 2003 ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Supplementary Protection Certificates for estradiol acetate

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0814 Netherlands ➤ Try a Free Trial PRODUCT NAME: LEVONORGESTREL EN ETHINYLESTRADIOL; NATIONAL REGISTRATION NO/DATE: RVG 117453 20151211; FIRST REGISTRATION: SK 17/0017/15-S 20150211
C/GB09/026 United Kingdom ➤ Try a Free Trial PRODUCT NAME: ESTRADIOL AND COMBINATIONS OF ESTRADIOL AND DIENOGEST, PREFERABLY ESTRADIOL VALERATE AND COMBINATIONS OF ESTRADIOL VALERATE AND DIENOGEST; REGISTERED: BE BE 327792 20081103; UK PL 00010/0576-0001 20081208
09/012 Ireland ➤ Try a Free Trial PRODUCT NAME: QLAIRA-ESTRADIOL VALERATE/DIENOGEST; NAT REGISTRATION NO/DATE: PA1410/58/1 20090109; FIRST REGISTRATION NO/DATE: BE327792 20081103
2009 00017 Denmark ➤ Try a Free Trial PRODUCT NAME: ETHINYLESTRADIOL (SOM BETADEXCLATHRAT) OG DROSPIRENON; NAT. REG. NO/DATE: 42417 (DK) 20080619; FIRST REG. NO/DATE: NL 33842 20070629
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Queensland Health
Chinese Patent Office
Mallinckrodt
QuintilesIMS
Teva
Johnson and Johnson
Chubb
Citi
Argus Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.